Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States
Two doses of RZV were effective in preventing HZ and PHN in adults aged ≥50 years, with durable protection. These findings underscore the importance of adhering to the recommended vaccination schedule.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Jeannie Song (ORCID: https://orcid.org/0009-0006-4349-5885)
- Harpreet S. Takhar (ORCID: https://orcid.org/0000-0002-2734-4896)
- Lina S. Sy (ORCID: https://orcid.org/0000-0003-2762-9266)
- Harry Seifert (ORCID: https://orcid.org/0000-0001-8048-5885)
- Yanjun Cheng (ORCID: https://orcid.org/0009-0003-3999-1884)
- Leticia I Vega Daily (ORCID: https://orcid.org/0009-0005-9675-4601)
- Driss Oraichi (ORCID: https://orcid.org/0009-0005-1921-7626)
- Jennifer H Ku (ORCID: https://orcid.org/0000-0001-9469-5875)
- Lei Qian (ORCID: https://orcid.org/0000-0001-8001-3992)
- Huifeng Yun (ORCID: https://orcid.org/0000-0002-0158-1797)
- Yi Luo (ORCID: https://orcid.org/0000-0001-8990-2470)
- Emily Rayens (ORCID: https://orcid.org/0000-0003-3369-3475)
- Hung Fu Tseng (ORCID: https://orcid.org/0000-0001-6184-6534)
- Rachel Cohen (ORCID: https://orcid.org/0000-0002-5277-1822)
- Jun Wu (ORCID: https://orcid.org/0000-0003-3227-4818)
Institutions
- Hawaii Department of Health (US)
- Kaiser Permanente (US)
- Universities at Shady Grove (US)
- National Blood Clot Alliance (US)
- Hawaii Permanente Medical Group (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1093/cid/ciaf329
- Citations
- 4
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Kaiser Permanente
- Moderna
- Genentech